Limited Mobile Version
Follow this company and never miss a research update
INDEX

InDex Pharmaceuticals

Market Cap 347.0M

InDex Pharmaceuticals är ett Stockholmsbaserat läkemedelsbolag med fokus på immunologiska sjukdomar. Ledande projektet cobitolimod är under utveckling för behandling av...

+ more
Today
Day High
5.65
5.6
Day Low
5.40
Day Open
5.55
Prev Close
5.55
VWAP
5.5
Volume
27K
Turnover
0.150M
Top Broker
NON
VWAP
5.6
Avg Volume
80K
Avg Turnover
0.447M
Top Brokers
NON/AVA
VWAP
5.5
Avg Volume
133K
Avg Turnover
0.733M
Top Brokers
NON/AVA
VWAP
5.5
Avg Volume
101K
Avg Turnover
0.555M
Top Brokers
NON/AVA
52 week summary
Price Range
4.4
Last
6.3
Beta
N/A
Market Cap
347.0M
Total Return
-0.9%
Trailing P/E
-8.4
Div Yield
0.0%
Shares Outstanding
62.5M
Next Earnings Date
17 Nov
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.


Relative Price Strength
Change 3 Months 4.3%
Change 12 Months -12.4%
Volume Trend
Average Volume 10 vs 60 Days 119.9%
Price VS
52 Week High -10.4%
50 Day Moving Average 3.1%
200 Day moving Average 10.7%

Add article markers

Compare InDex Pharmaceuticals to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Peter Zerhouni, CEO
  • Johan Giléus, CFO
  • Executive board
  • Wenche Rolfsen, Chairman of the board
  • Uli Hacksell
  • Lennart Hansson
  • Stig Lökke Pedersen
  • Andreas Pennervall
Last updated: 2017-03-27 Source: Redeye
Major Owners Equity Votes
SEB Venture Capital 23.4%
23.4%
Stiftelsen Industrifonden 20.6%
20.6%
NeoMed 10.5%
10.5%
Staffan Rasjö 5.0%
5.0%
SEB Stiftelsen 2.9%
2.9%
Avanza Pension 2.5%
2.5%
Dzevad Bjelak 1.8%
1.8%
Danske Bank 1.7%
1.7%
Rune Pettersson 1.6%
1.6%
Nordnet Pension 1.5%
1.5%
Last updated: 2017-07-18 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
1 Purchases
+ 175,000
0 Sales
- 0
Last 24 weeks
1 Purchases
+ 175,000
0 Sales
- 0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Catalyst Potential is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Sign up Login
Source: Millistream FI
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2014
  •  
  • -65.4%
  • -48.5%
  • 144.7%
  • -26.7%
  • -27.0%
  • -32.9%
  •  
  • -0.25
  • -0.25
  • 0.00
  •  
  • 60.3
  •  
  • -39.4
  • 0.0
  • 0.0
  • 0.0
  • -0.9
  • 3.3
  • 3.2
  • 0.0
  •  
  • 66.7%
  • 100.0%
  • -39
  • -9
  • 1.0
  • 2014
  •  
  •  
  • 44
  • 2
  • 0
  • 0
  • 45
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 46
  •  
  •  
  • 4
  • 4
  • 6
  • 15
  • 0
  • 0
  • 0
  • 15
  • 0
  • 0
  • 30
  • 0
  • 30
  • 46
  • 2014
  • 45
  • -57
  • -0
  • -12
  • 3
  • -10
  • 0
  • -9
  • 2
  • 0
  • -14
  • 2014 Q3
  • 45
  • -57
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2014 Q4
  • 45
  • -57
  • -12
  • -0
  • 0
  • 0
  • -12
  • 0
  • 2
  • 0
  • -10
  • -4
  • -15
  • 2015
  •  
  • -193.1%
  • -148.5%
  • 326.3%
  • -7,813.6%
  • -7,838.8%
  • -7,947.1%
  •  
  • -0.50
  • -0.50
  • 0.00
  •  
  • 60.3
  •  
  • -2.7
  • 0.0
  • 0.0
  • 0.0
  • -7.1
  • 0.1
  • 0.1
  • 0.0
  •  
  • 6.6%
  • 100.0%
  • -3
  • -2
  • 0.0
  • 2015
  •  
  •  
  • 7
  • 1
  • 0
  • 0
  • 8
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 8
  •  
  •  
  • 4
  • 1
  • 3
  • 8
  • 0
  • 0
  • 0
  • 8
  • 0
  • 0
  • 1
  • 0
  • 1
  • 8
  • 2015
  • 0
  • -30
  • -0
  • -29
  • 0
  • -29
  • 0
  • -29
  • -7
  • 0
  • -36
  • 2015 Q1
  • 0
  • -30
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q2
  • 0
  • -30
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 0
  • -30
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 0
  • -30
  • -29
  • -0
  • 0
  • 0
  • -29
  • 0
  • -0
  • 0
  • -30
  • 0
  • -30
  • 2016
  •  
  • -46.4%
  • -41.8%
  • 1,860.3%
  • -22,433.0%
  • -22,471.0%
  • -23,451.7%
  •  
  • -0.66
  • -0.66
  • 0.00
  •  
  • 62.4
  •  
  • -187.6
  • 0.0
  • 0.0
  • 0.0
  • -1,066.0
  • 4.8
  • 4.7
  • 0.0
  •  
  • 91.3%
  • 100.0%
  • -188
  • -10
  • 0.0
  • 2016
  •  
  •  
  • 193
  • 1
  • 0
  • 0
  • 194
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 194
  •  
  •  
  • 6
  • 5
  • 7
  • 17
  • 0
  • 0
  • 0
  • 17
  • 0
  • 0
  • 177
  • 0
  • 177
  • 194
  • 2016
  • 0
  • -40
  • -0
  • -40
  • 0
  • -40
  • 0
  • -39
  • 8
  • -0
  • -32
  • 2016 Q1
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q2
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q3
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q4
  • 0
  • -40
  • -39
  • -0
  • 0
  • 0
  • -40
  • 0
  • -2
  • 0
  • -41
  • 0
  • -41
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Sign up Login
Last updated: 2017-09-08 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.


Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.